|
No records
|
|
231 |
Farhoudian A., Radfar S.R., Ardabili H.M., Rafei P., Ebrahimi M., Zonoozi A.K., De Jong C.A.J., Vahidi M., Yunesian M., Kouimtsidis C., Arunogiri S., Hansen H., Brady K.T., Potenza M.N., Baldacchino A.M., Ekhtiari H., Abagiu A.O., Abouna F.D.N., Ahmed M.H., Al-Ansari B., Al-Khair F.M.A., Almaqbali M.H., Ambekar A., Arya S., Asebikan V.O., Ayasreh M.A., Basu D., Benmebarek Z., Bhad R., Blaise M., Bonnet N., Brasch J., Broers B., Busse A., Butner J.L., Camilleri M., Campello G., Carra G., Celic I., Chalabianloo F., Chaturvedi A., Cherpitel J.J.E.N., Clark K.J., Cyders M.A., de Bernardis E., Deilamizade A., Derry J.E., Dhagudu N.K., Dolezalova P., Dom G., Dunlop A.J., Elhabiby M.M., Elkholy H., Essien N.F., Farah G.I., Ferri M., Floros G.D., Friedman C., Fuderanan C.H., Gerra G., Ghosh A., Gogia M., Grammatikopoulos I.A., Grandinetti P., Guirguis A., Gutnisky D., Haber P.S., Hassani-Abharian P., Hooshyari Z., Ibrahim I.I.M., Ieong H.F.-H., Indradewi R.N., Iskandar S., Isra T.N., Jain S., James S., Javadi S.M.H., Joe K.H., Jokubonis D., Jovanova A.T., Kamal R.M., Kantchelov A.I., Kathiresan P., Katzman G., Kawale P., Kern A.M., Kessler F.H.P., Kim S.-G.S., Kimball A.M., Kljucevic Z., Kurniasanti K.S., Lev R., Lee H.K., Lengvenyte A., Lev-Ran S., Mabelya G.S., Mahi M.A.E., Maphisa J.M., Maremmani I., Masferrer L., Massah O., McCambridge O., McGovern G.G., Min A.K., Moghanibashi-Mansourieh A., Mora-Rios J., Mudalige I.U.K., Mukherjee D., Munira P.M., Myers B., Menon T. N. J., Narasimha V.L., Ndionuka N., Nejatisafa A.-A., Niaz K., Nizami A.T., Nuijens J.H., Orsolini L., Oum V., Oyemade A.A., Palavra I.R., Pant S.B., Paredes J., Peyron E., Quirós R.A., Qurishi R., Rafiq N.U.Z., Raghavendra Rao R., Ratta-Apha W., Raymond K.-L., Reimer J., Renaldo E., Rezapour T., Robertson J.R., Roncero C., Roub F., Rubenstein E.J., Rupp C.I., Saenz E., Salehi M., Samartzis L., Sarubbo L.B., Segrec N., Shah B., Shen H., Shirasaka T., Shoptaw S., Sintango F.M., Sosa V.A., Subata E., Sztycberg N., Taghizadeh F., Wee Teck J.B.T., Tjagvad C., Torrens M., Twala J.M., Vadivel R., Volpicelli J.R., Weijs J., Wintoniw S.M., Wittayanookulluk A., Wojnar M., Yasir S., Yitayih Y., Zhao M., ISAM Global Survey Consortium (ISAM-GSC) |
25631625900;36019651400;55658200400;57218199674;57218203004;57218205554;55394697400;57203060812;14622058700;6602323007;55912287400;57221996850;7101818468;7006591634;6603786612;26632924600;55021572500;57221605725;57221411272;56996118200;55549232500;57221411355;35749590300;35463222300;57221410006;57221410448;18833291700;57219202850;55789741800;6603894892;15135243700;57189041459;7003868723;57196510693;56816710600;57221410155;56400851700;7003818736;24176502200;26026739900;54936844000;57358665500;57221410761;6504408224;55604104700;56059025100;57221409824;57203836122;6603422138;12768470700;57219674374;26767656700;55086535500;57191041815;57221411550;8871569800;12768168000;57221411410;57210375852;55578764500;36833820900;57205763778;27367905800;55487378900;55496109900;57221411047;7004422180;54892046900;36607951600;57216708013;57193806115;57221410095;37004580200;57221604184;57207211289;57216621884;57207842636;15062725000;57188646762;57221411023;36996943600;24468101500;57023935300;57221410517;55928375400;55031071400;57202970264;57221410531;35420584800;57203155640;57209262171;8913859800;8600274900;57189340754;23019092700;57221410613;57223919852;57200792839;7003948428;6507438528;57044778200;56527137000;57221410507;57221411329;56059054800;6506077151;57214574855;57197364393;57221410358;7202684194;57200567557;56272241600;57221410263;55666521300;57194102646;12144358600;7004198198;55376767200;57217227990;16234058300;57225265059;36114863900;57221411223;57205355338;57221409971;55735687800;57221410341;57358663600;35604346900;56783754400;56000939600;57221410809;56968163500;57205640157;7003524112;57191926633;57221411128;7006106435;26656074800;57226311750;36633076300;57221409908;24476669600;57219874143;57216762422;7005625709;7003465287;57221409902;57221409982;56616079200;57221410011;55802145800;57221409677;57188537200;7006681890;57221411350;57219874702;57209053124;57221410085;57221410695;55151590700;6701757799;57221410275;57204013732;55185317400; |
A Global Survey on Changes in the Supply, Price, and Use of Illicit Drugs and Alcohol, and Related Complications During the 2020 COVID-19 Pandemic |
2021 |
Frontiers in Psychiatry |
12 |
|
646206 |
|
|
|
6 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85113236018&doi=10.3389%2ffpsyt.2021.646206&partnerID=40&md5=583fc4953970f4d964584bcd9a7d5b02 |
Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran; Department of Neuroscience and Addiction, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, Tehran, Iran; Integrated Substance Abuse Programs Department, University of California, Los Angeles, Los Angeles, CA, United States; Psychiatry and Behavioral Sciences Research Center, Faculty of Medicine, Ibn-e-Sina Hospital, Mashhad University of Medical Sciences, Mashhad, Iran; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Psychology, Faculty of Psychology and Education, University of Tehran, Tehran, Iran; Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran; Behavioral Science Institute, Radboud University, Nijmegen, Netherlands; School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; Surrey and Borders Partnership National Health Service Foundation Trust, Leatherhead, United Kingdom; Turning Point, Eastern Health, Box Hill, VIC, Australia; Departments of Anthropology and Psychiatry, New York University, New York, NY, United States; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States; Yale School of Medicine, Connecticut Council on Problem Gambling and Connecticut Mental Health Center, New Haven, CT, United States; Division of Population and Behavior Sciences, Medical School, University of St Andrews, St Andrews, United Kingdom; Laureate Institute for Brain Research, Tulsa, OK, United States; National Institute for Infectious Diseases, Prof. Dr. Matei Bals-Arena OMT Department, Romania; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon; Alamal psychiatric hospital, Dubai, United Arab Emirates; Sydney Medical School, University of SydneyNSW, Australia; Al Ahliyya Amman University, Amman, Jordan; Ministry of Health, Muscat, Oman; Department of Psychiatry and National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India; State Drug Dependence Treatment Centre, Institute of Mental Health, Pt BDS University of Health Sciences, India; Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria; Addiction Medicine Clinic, Jordan; Drug De-addiction and Treatment Centre, Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India; Addiction Medicine Clinic, Mila, Algeria; Centre medical Marmottan, France; Réseau de Prévention des Addictions (RESPADD), France; Department of Psychiatry and Behavioural Neurosciences, Michael DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada; Geneva University Hospitals, Switzerland; United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; CUNY School of Medicine, New York, United States; Agenzija Sedqa, Malta; Department of Medicine and Surgery, University Milan-Bicocca, Italy; University Psychiatric Hospital Vrapce-Zagreb, Croatia; Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway; Department of Biochemistry, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India; Addiction Medicine Clinic, Mexico; Addiction Crisis Solutions, United States; Department of Psychology, Indiana University Purdue University-Indianapolis, United States; SerT Lentini, ASP Siracusa, Italy; Rebirth Charity Society NGO, Tehran, Iran; Serenity Vista Addiction Treatment Center, Panama; Department of Psychiatry, ESIC Medical College, Hyderabad, Telangana, India; National Institute of Mental Health, Czech Republic; Collaborative Antwerp Psychiatric Research Institute (CAPRI), Antwerp University (UA), Belgium; Drug & Alcohol Clinical Services, Hunter New England Local Health District, Australia; Ain Shams University, Cairo, Egypt; Department of Neurology and Psychiatry, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Centre for Research and Information on Substance Abuse, Nigeria; Addiction Medicine Clinic, Syrian Arab Republic; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Italy; Department of Psychiatry, Aristotle University of Thessaloniki, Greece; Brown University and Lifespan Health System, Providence, RI, United States; Fuderanan Mental Health Clinic, Philippines; Drug De-addiction & Treatment Centre, Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India; Georgian Harm Reduction Network, Georgia; Organization Against Drugs, Primary Care Health Center, Veria, Greece; Addictions Services (Ser.D.), Department of Territorial Services, ASL Teramo, Italy; Swansea University Medical School, Institute of Life Sciences 2, Singleton CampusSA2 8PP, United Kingdom; Universidad de Buenos Aires, Argentina; University of Sydney, Australia; Institutes for Cognitive Science Studies (IRICSS), Brain and Cognition Clinic, Tehran, Iran; Tehran University of Medical Sciences, Tehran, Iran; Department of Anesthesiology, Yale University, United States; Drugs Rehabilitation Center, National Narcotics Board of Indonesia, Indonesia; Department of Psychiatry, Universitas Padjadjaran, Bandung, West Java, Indonesia; National Institute of Education, Sri Lanka; Department of Psychiatry, Heritage Institute of Medical Sciences (HIMS), Varanasi, India; Univeristi Malaysia Sabah, Malaysia; Department of Social Work, University of Social Welfare & Rehabilitation Sciences, Tehran, Iran; National Center for Mental Health of Korea, South Korea; Republican Center for Addictive Disorders, Lithuania; Addiction Medicine Clinic, North Macedonia; Naufar Institute, Doha, Qatar; The Kantchelov Clinic, Sofia, Bulgaria; Mount Sinai Medical Center, New York, United States; African Institute for Development Policy, Malawi; Sobriety Centers of New Hampshire, United States; Federal University of Rio Grande do Sul, Brazil; Pusan National University Yangsan Hospital, Department of Neuropsychiatry, Yangsan, South Korea; Chatham House, United States; Institute for Public Health of Split-Dalmatia County, Croatia; Faculty of Medicine, Universitas Indonesia-Ciptomangunkusumo Hospital, Indonesia; Scripps Mercy Hospital, San Diego, United States; Department of Psychiatry, The Catholic University of Korea, Seoul, South Korea; Faculty of Medicine, Institute of Clinical Medicine, Psychiatric Clinic, Vilnius University, Vilnius, Lithuania; Israel Center on Addiction, Netanya, Israel; Community Health Work, Tanzania; Hayat Center for Treatment and Psycho-social Rehabilitation, Khartoum, Sudan; University of Botswana, Botswana; V.P. Dole, Dual Disorder Unit, Santa Chiara University Hospital, University of Pisa, Italy; CAS Girona, Department of Psychology, University of Girona, Spain; Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran; Community addiction team, Southern Health and Social Care Trust, United Kingdom; Priority Medical Clinic, Dublin, Ireland; Save the Children International Organization, Burma; Dirección de Investigaciones Epidemiológicas y Sociales, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, United States; Department of Psychiatry, Faculty of Medicine, Sir John Kotelawala Defence University, Sri Lanka; Centre for Addiction Medicine, NIMHANS, Bangalore, India; Kleopatra Kodric, Irena Nisic, Slovenia; Alcohol Tobacco and Other Drug Research Unit, South African Medical Research Council, South Africa; NIMHANS, Bangalore, India; Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, India; Federal Neuropsychiatric Hospital, Calabar, Nigeria; Department of Psychiatry, Psychosomatic Research Center, Tehran University of Medical Sciences, Tehran, Iran; Institute of Psychiatry, WHO Collaborating Center for Mental Health, Pakistan; Brijder Addiction Care, Zaandam, Netherlands; Department of Clinical Neurosciences/DIMSC, School of Medicine, Polytechnic University of Marche, Ancona, Italy; Koh Kong Provincial Hospital, Cambodia; Kaiser Permanente, United States; Psychiatric hospital Sveti Ivan, Zagreb, Croatia; Department of Psychiatry and mental health, Institute of Medicine, Tribhuvan University, Nepal; Universidad de El Salvador, El Salvador; AddiPsy, Lyon, France; Addiction Medicine Clinic, Costa Rica; Novadic-Kentron Addiction Care Network, Vught, Netherlands; Phoenix Foundation for Research and Development, Pakistan; Barwon Health, Geelong, Australia; Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; University of the Sunshine Coast (USC)QLD, Australia; Center for Interdisciplinary Addiction Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drugs Rehabilitation Center, National Narcotics Board of Indonesia; Department of Cognitive Psychology, Institute for Cognitive Science Studies, Tehran, Iran; Usher Institute, University of Edinburgh, United Kingdom; Psychiatry Service, University of Salamanca Health Care Complex, Salamanca, Spain; PGIMER, Chandigarh, India; Street Health Centre, Canada; Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical University Innsbruck, Austria; Department of Neurosciences and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran; Medical School, University of Cyprus, Cyprus; Clínica Psiquiátrica de la Facultad de Medicina, Uruguay; Center for Treatment of Drug addiction, University Psychiatric Clinic, Ljubljana, Slovenia; Department of Psychiatry, Patan Academy of Health Sciences, School of Medicine, Lagankhel, Nepal; Department of Psychiatry, Second Xiangya Hospital, Central South University, China; Department of Psychiatry, Teine Keijinkai Medical Center, Japan; David Geffen School of Medicine at UCLA, Department of Family Medicine, United States; Health Professions Councils of Namibia, Namibia; Addiction Medicine Clinic, Uruguay; Asociasion Programa Andres Argentina, Argentina; Mazandaran University of Medical Sciences, Mazandaran, Iran; MRC/CSO SPHSU, University of Glasgow, United Kingdom; Gladsaxe Substance Use Disorder Treatment Centre, Denmark; Institut de Neuropsiquiatria i Addiccions, IMIM-Hospital del Mar, Medical Research, Barcelona, Spain; NACADA, Kenya; Waikato District Health Board (WDHB, Hamilton, New Zealand; Institute of Addiction Medicine, United States; Jellinek, Amsterdam, Netherlands; Addictions Foundation of Manitoba, Canada; Thanyarak Chiangmai Hospital, Thailand; Medical University of Warsaw, Warsaw, Poland; Jimma University, Ethiopia; Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, China |
Farhoudian, A., Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran; Radfar, S.R., Department of Neuroscience and Addiction, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, Tehran, Iran, Integrated Substance Abuse Programs Department, University of California, Los Angeles, Los Angeles, CA, United States; Ardabili, H.M., Psychiatry and Behavioral Sciences Research Center, Faculty of Medicine, Ibn-e-Sina Hospital, Mashhad University of Medical Sciences, Mashhad, Iran, Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Rafei, P., Department of Psychology, Faculty of Psychology and Education, University of Tehran, Tehran, Iran, Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran; Ebrahimi, M., Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran; Zonoozi, A.K., Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; De Jong, C.A.J., Behavioral Science Institute, Radboud University, Nijmegen, Netherlands; Vahidi, M., Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran; Yunesian, M., School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; Kouimtsidis, C., Surrey and Borders Partnership National Health Service Foundation Trust, Leatherhead, United Kingdom; Arunogiri, S., Turning Point, Eastern Health, Box Hill, VIC, Australia; Hansen, H., Departments of Anthropology and Psychiatry, New York University, New York, NY, United States; Brady, K.T., Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States; Potenza, M.N., Yale School of Medicine, Connecticut Council on Problem Gambling and Connecticut Mental Health Center, New Haven, CT, United States; Baldacchino, A.M., Division of Population and Behavior Sciences, Medical School, University of St Andrews, St Andrews, United Kingdom; Ekhtiari, H., Laureate Institute for Brain Research, Tulsa, OK, United States; Abagiu, A.O., National Institute for Infectious Diseases, Prof. Dr. Matei Bals-Arena OMT Department, Romania; Abouna, F.D.N., Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon; Ahmed, M.H., Alamal psychiatric hospital, Dubai, United Arab Emirates; Al-Ansari, B., Sydney Medical School, University of SydneyNSW, Australia; Al-Khair, F.M.A., Al Ahliyya Amman University, Amman, Jordan; Almaqbali, M.H., Ministry of Health, Muscat, Oman; Ambekar, A., Department of Psychiatry and National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India; Arya, S., State Drug Dependence Treatment Centre, Institute of Mental Health, Pt BDS University of Health Sciences, India; Asebikan, V.O., Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria; Ayasreh, M.A., Addiction Medicine Clinic, Jordan; Basu, D., Drug De-addiction and Treatment Centre, Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India; Benmebarek, Z., Addiction Medicine Clinic, Mila, Algeria; Bhad, R., Department of Psychiatry and National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India; Blaise, M., Centre medical Marmottan, France; Bonnet, N., Réseau de Prévention des Addictions (RESPADD), France; Brasch, J., Department of Psychiatry and Behavioural Neurosciences, Michael DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada; Broers, B., Geneva University Hospitals, Switzerland; Busse, A., United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Butner, J.L., CUNY School of Medicine, New York, United States; Camilleri, M., Agenzija Sedqa, Malta; Campello, G., United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Carra, G., Department of Medicine and Surgery, University Milan-Bicocca, Italy; Celic, I., University Psychiatric Hospital Vrapce-Zagreb, Croatia; Chalabianloo, F., Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway; Chaturvedi, A., Department of Biochemistry, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India; Cherpitel, J.J.E.N., Addiction Medicine Clinic, Mexico; Clark, K.J., Addiction Crisis Solutions, United States; Cyders, M.A., Department of Psychology, Indiana University Purdue University-Indianapolis, United States; de Bernardis, E., SerT Lentini, ASP Siracusa, Italy; Deilamizade, A., Rebirth Charity Society NGO, Tehran, Iran; Derry, J.E., Serenity Vista Addiction Treatment Center, Panama; Dhagudu, N.K., Department of Psychiatry, ESIC Medical College, Hyderabad, Telangana, India; Dolezalova, P., National Institute of Mental Health, Czech Republic; Dom, G., Collaborative Antwerp Psychiatric Research Institute (CAPRI), Antwerp University (UA), Belgium; Dunlop, A.J., Drug & Alcohol Clinical Services, Hunter New England Local Health District, Australia; Elhabiby, M.M., Ain Shams University, Cairo, Egypt; Elkholy, H., Department of Neurology and Psychiatry, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Essien, N.F., Centre for Research and Information on Substance Abuse, Nigeria; Farah, G.I., Addiction Medicine Clinic, Syrian Arab Republic; Ferri, M., European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Italy; Floros, G.D., Department of Psychiatry, Aristotle University of Thessaloniki, Greece; Friedman, C., Brown University and Lifespan Health System, Providence, RI, United States; Fuderanan, C.H., Fuderanan Mental Health Clinic, Philippines; Gerra, G., United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Ghosh, A., Drug De-addiction & Treatment Centre, Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India; Gogia, M., Georgian Harm Reduction Network, Georgia; Grammatikopoulos, I.A., Organization Against Drugs, Primary Care Health Center, Veria, Greece; Grandinetti, P., Addictions Services (Ser.D.), Department of Territorial Services, ASL Teramo, Italy; Guirguis, A., Swansea University Medical School, Institute of Life Sciences 2, Singleton CampusSA2 8PP, United Kingdom; Gutnisky, D., Universidad de Buenos Aires, Argentina; Haber, P.S., University of Sydney, Australia; Hassani-Abharian, P., Institutes for Cognitive Science Studies (IRICSS), Brain and Cognition Clinic, Tehran, Iran; Hooshyari, Z., Tehran University of Medical Sciences, Tehran, Iran; Ibrahim, I.I.M., Ain Shams University, Cairo, Egypt; Ieong, H.F.-H., Department of Anesthesiology, Yale University, United States; Indradewi, R.N., Drugs Rehabilitation Center, National Narcotics Board of Indonesia, Indonesia; Iskandar, S., Department of Psychiatry, Universitas Padjadjaran, Bandung, West Java, Indonesia; Isra, T.N., National Institute of Education, Sri Lanka; Jain, S., Department of Psychiatry, Heritage Institute of Medical Sciences (HIMS), Varanasi, India; James, S., Univeristi Malaysia Sabah, Malaysia; Javadi, S.M.H., Department of Social Work, University of Social Welfare & Rehabilitation Sciences, Tehran, Iran; Joe, K.H., National Center for Mental Health of Korea, South Korea; Jokubonis, D., Republican Center for Addictive Disorders, Lithuania; Jovanova, A.T., Addiction Medicine Clinic, North Macedonia; Kamal, R.M., Naufar Institute, Doha, Qatar; Kantchelov, A.I., The Kantchelov Clinic, Sofia, Bulgaria; Kathiresan, P., Department of Psychiatry and National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India; Katzman, G., Mount Sinai Medical Center, New York, United States; Kawale, P., African Institute for Development Policy, Malawi; Kern, A.M., Sobriety Centers of New Hampshire, United States; Kessler, F.H.P., Federal University of Rio Grande do Sul, Brazil; Kim, S.-G.S., Pusan National University Yangsan Hospital, Department of Neuropsychiatry, Yangsan, South Korea; Kimball, A.M., Chatham House, United States; Kljucevic, Z., Institute for Public Health of Split-Dalmatia County, Croatia; Kurniasanti, K.S., Faculty of Medicine, Universitas Indonesia-Ciptomangunkusumo Hospital, Indonesia; Lev, R., Scripps Mercy Hospital, San Diego, United States; Lee, H.K., Department of Psychiatry, The Catholic University of Korea, Seoul, South Korea; Lengvenyte, A., Faculty of Medicine, Institute of Clinical Medicine, Psychiatric Clinic, Vilnius University, Vilnius, Lithuania; Lev-Ran, S., Israel Center on Addiction, Netanya, Israel; Mabelya, G.S., Community Health Work, Tanzania; Mahi, M.A.E., Hayat Center for Treatment and Psycho-social Rehabilitation, Khartoum, Sudan; Maphisa, J.M., University of Botswana, Botswana; Maremmani, I., V.P. Dole, Dual Disorder Unit, Santa Chiara University Hospital, University of Pisa, Italy; Masferrer, L., CAS Girona, Department of Psychology, University of Girona, Spain; Massah, O., Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran; McCambridge, O., Community addiction team, Southern Health and Social Care Trust, United Kingdom; McGovern, G.G., Priority Medical Clinic, Dublin, Ireland; Min, A.K., Save the Children International Organization, Burma; Moghanibashi-Mansourieh, A., Department of Social Work, University of Social Welfare & Rehabilitation Sciences, Tehran, Iran; Mora-Rios, J., Dirección de Investigaciones Epidemiológicas y Sociales, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, United States; Mudalige, I.U.K., Department of Psychiatry, Faculty of Medicine, Sir John Kotelawala Defence University, Sri Lanka; Mukherjee, D., Centre for Addiction Medicine, NIMHANS, Bangalore, India; Munira, P.M., Kleopatra Kodric, Irena Nisic, Slovenia; Myers, B., Alcohol Tobacco and Other Drug Research Unit, South African Medical Research Council, South Africa; Menon T. N., J., NIMHANS, Bangalore, India; Narasimha, V.L., Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, India; Ndionuka, N., Federal Neuropsychiatric Hospital, Calabar, Nigeria; Nejatisafa, A.-A., Department of Psychiatry, Psychosomatic Research Center, Tehran University of Medical Sciences, Tehran, Iran; Niaz, K., United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Nizami, A.T., Institute of Psychiatry, WHO Collaborating Center for Mental Health, Pakistan; Nuijens, J.H., Brijder Addiction Care, Zaandam, Netherlands; Orsolini, L., Department of Clinical Neurosciences/DIMSC, School of Medicine, Polytechnic University of Marche, Ancona, Italy; Oum, V., Koh Kong Provincial Hospital, Cambodia; Oyemade, A.A., Kaiser Permanente, United States; Palavra, I.R., Psychiatric hospital Sveti Ivan, Zagreb, Croatia; Pant, S.B., Department of Psychiatry and mental health, Institute of Medicine, Tribhuvan University, Nepal; Paredes, J., Universidad de El Salvador, El Salvador; Peyron, E., AddiPsy, Lyon, France; Quirós, R.A., Addiction Medicine Clinic, Costa Rica; Qurishi, R., Novadic-Kentron Addiction Care Network, Vught, Netherlands; Rafiq, N.U.Z., Phoenix Foundation for Research and Development, Pakistan; Raghavendra Rao, R., Barwon Health, Geelong, Australia; Ratta-Apha, W., Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; Raymond, K.-L., University of the Sunshine Coast (USC)QLD, Australia; Reimer, J., Center for Interdisciplinary Addiction Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Renaldo, E., Drugs Rehabilitation Center, National Narcotics Board of Indonesia; Rezapour, T., Department of Cognitive Psychology, Institute for Cognitive Science Studies, Tehran, Iran; Robertson, J.R., Usher Institute, University of Edinburgh, United Kingdom; Roncero, C., Psychiatry Service, University of Salamanca Health Care Complex, Salamanca, Spain; Roub, F., PGIMER, Chandigarh, India; Rubenstein, E.J., Street Health Centre, Canada; Rupp, C.I., Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical University Innsbruck, Austria; Saenz, E., United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Salehi, M., Department of Neurosciences and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran; Samartzis, L., Medical School, University of Cyprus, Cyprus; Sarubbo, L.B., Clínica Psiquiátrica de la Facultad de Medicina, Uruguay; Segrec, N., Center for Treatment of Drug addiction, University Psychiatric Clinic, Ljubljana, Slovenia; Shah, B., Department of Psychiatry, Patan Academy of Health Sciences, School of Medicine, Lagankhel, Nepal; Shen, H., Department of Psychiatry, Second Xiangya Hospital, Central South University, China; Shirasaka, T., Department of Psychiatry, Teine Keijinkai Medical Center, Japan; Shoptaw, S., David Geffen School of Medicine at UCLA, Department of Family Medicine, United States; Sintango, F.M., Health Professions Councils of Namibia, Namibia; Sosa, V.A., Addiction Medicine Clinic, Uruguay; Subata, E., Republican Center for Addictive Disorders, Lithuania; Sztycberg, N., Asociasion Programa Andres Argentina, Argentina; Taghizadeh, F., Mazandaran University of Medical Sciences, Mazandaran, Iran; Wee Teck, J.B.T., MRC/CSO SPHSU, University of Glasgow, United Kingdom; Tjagvad, C., Gladsaxe Substance Use Disorder Treatment Centre, Denmark; Torrens, M., Institut de Neuropsiquiatria i Addiccions, IMIM-Hospital del Mar, Medical Research, Barcelona, Spain; Twala, J.M., NACADA, Kenya; Vadivel, R., Waikato District Health Board (WDHB, Hamilton, New Zealand; Volpicelli, J.R., Institute of Addiction Medicine, United States; Weijs, J., Jellinek, Amsterdam, Netherlands; Wintoniw, S.M., Addictions Foundation of Manitoba, Canada; Wittayanookulluk, A., Thanyarak Chiangmai Hospital, Thailand; Wojnar, M., Medical University of Warsaw, Warsaw, Poland; Yasir, S., Institute of Psychiatry, WHO Collaborating Center for Mental Health, Pakistan; Yitayih, Y., Jimma University, Ethiopia; Zhao, M., Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, China; ISAM Global Survey Consortium (ISAM-GSC) |
Background and Aims: COVID-19 has infected more than 77 million people worldwide and impacted the lives of many more, with a particularly devastating impact on vulnerable populations, including people with substance use disorders (SUDs). Quarantines, travel bans, regulatory changes, social distancing, and “lockdown” measures have affected drug and alcohol supply chains and subsequently their availability, price, and use patterns, with possible downstream effects on presentations of SUDs and demand for treatment. Given the lack of multicentric epidemiologic studies, we conducted a rapid global survey within the International Society of Addiction Medicine (ISAM) network in order to understand the status of substance-use patterns during the current pandemic. Design: Cross-sectional survey. Setting: Worldwide. Participants: Starting on April 4, 2020 during a 5-week period, the survey received 185 responses from 77 countries. Measurements: To assess addiction medicine professionals' perceived changes in drug and alcohol supply, price, use pattern, and related complications during the COVID-19 pandemic. Findings: Participants reported (among who answered “decreased” or “increased”) a decrease in drug supply (69.0%) and at the same time an increase in price (95.3%) globally. With respect to changes in use patterns, an increase in alcohol (71.7%), cannabis (63.0%), prescription opioids (70.9%), and sedative/hypnotics (84.6%) use was reported, while the use of amphetamines (59.7%), cocaine (67.5%), and opiates (58.2%) was reported to decrease overall. Conclusions: The global report on changes in the availability, use patterns, and complications of alcohol and drugs during the COVID-19 pandemic should be considered in making new policies and in developing mitigating measures and guidelines during the current pandemic (and probable future ones) in order to minimize risks to people with SUD. © Copyright © 2021 Farhoudian, Radfar, Mohaddes Ardabili, Rafei, Ebrahimi, Khojasteh Zonoozi, De Jong, Vahidi, Yunesian, Kouimtsidis, Arunogiri, Hansen, Brady, ISAM Global Survey Consortium (ISAM-GSC), Potenza, Baldacchino and Ekhtiari. |
addiction; behavioral addiction; COVID-19; global survey; illicit drug market; substance use disorder |
alcohol; cannabis; illicit drug; addiction medicine; adult; Article; coronavirus disease 2019; drug bioavailability; drug industry; female; gambling; health care personnel; health service; human; male; pandemic; pharmacist; prescription; questionnaire; substance use |
Frontiers Media S.A. |
16640640 |
|
|
Article |
Q1 |
1363 |
2668 |
|
|
|
232 |
Raharjanti N.W., Wiguna T., Purwadianto A., Soemantri D., Bardosono S., Poerwandari E.K., Mahajudin M.S., Ramadianto A.S., Alfonso C.A., Findyartini A., Nugrahadi N.R., Lazuardi M.Q., Subroto P.A.M., Saroso O.J.D.A., Levania M.K. |
57226872499;24367785700;18635479200;36640659100;21933841000;25628305200;57218600581;57226862690;7004331573;56543777300;57221694462;57226862998;57208444972;57226865761;57226868672; |
Clinical Reasoning in Forensic Psychiatry: Concepts, Processes, and Pitfalls |
2021 |
Frontiers in Psychiatry |
12 |
|
691377 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85113172545&doi=10.3389%2ffpsyt.2021.691377&partnerID=40&md5=a63e42686ad595c41e376dfb2ea2ffc6 |
Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Psychiatry, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Department of Forensic and Medicolegal, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Department of Medical Education, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Nutrition, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Faculty of Psychology, Universitas Indonesia, Jakarta, Indonesia; Department of Psychiatry, Airlangga University, Surabaya, Indonesia; Department of Psychiatry, Columbia University, New York, NY, United States |
Raharjanti, N.W., Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Psychiatry, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Wiguna, T., Department of Psychiatry, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Purwadianto, A., Department of Forensic and Medicolegal, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Soemantri, D., Department of Medical Education, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Bardosono, S., Department of Nutrition, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Poerwandari, E.K., Faculty of Psychology, Universitas Indonesia, Jakarta, Indonesia; Mahajudin, M.S., Department of Psychiatry, Airlangga University, Surabaya, Indonesia; Ramadianto, A.S., Department of Psychiatry, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Alfonso, C.A., Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Psychiatry, Columbia University, New York, NY, United States; Findyartini, A., Department of Medical Education, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Nugrahadi, N.R., Department of Psychiatry, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Lazuardi, M.Q., Department of Psychiatry, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Subroto, P.A.M., Department of Psychiatry, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Saroso, O.J.D.A., Department of Psychiatry, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Levania, M.K., Department of Psychiatry, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas IndonesiaJakarta, Indonesia |
Forensic psychiatrists are often sought by the court of law to provide professional opinion on specific legal matters that have a major impact on the evaluee and possibly society at large. The quality of that opinion and recommendations rely on the quality of the analysis from the assessment results conducted by the psychiatrist. However, the definition and scope of a forensic psychiatric analysis is not clear. While existing literature on forensic psychiatric analysis generally includes organizing information, identifying relevant details, and formulating a set of forensic psychiatric opinions as components, there is no explicit and unified definition of these terms and process. This lack of clarity and guidelines may hinder forensic psychiatry from achieving its goal of providing objective information to the court or other relevant parties. Forensic psychiatric analysis exhibits numerous parallels to clinical reasoning in other fields of medicine. Therefore, this review aims to elaborate forensic psychiatric analysis through the lens of clinical reasoning, which has been developed by incorporating advances in cognitive sciences. We describe forensic psychiatric analysis through three prominent clinical reasoning theories: hypothetico-deductive model, illness script theory, and dual process theory. We expand those theories to elucidate how forensic psychiatrists use clinical reasoning not only to diagnose mental disorders, but also to determine mental capacities as requested by law. Cognitive biases are also described as potential threat to the accuracy of the assessment and analysis. Additionally, situated cognition theory helps elucidate how contextual factors influence risk of errors. Understanding the processes involved in forensic psychiatric analysis and their pitfalls can assist forensic psychiatrists to be aware of and try to mitigate their bias. Debiasing strategies that have been implemented in other fields of medicine to mitigate errors in clinical reasoning can be adapted for forensic psychiatry. This may also shape the training program of general psychiatrists and forensic psychiatrists alike. © Copyright © 2021 Raharjanti, Wiguna, Purwadianto, Soemantri, Bardosono, Poerwandari, Mahajudin, Ramadianto, Alfonso, Findyartini, Nugrahadi, Lazuardi, Subroto, Saroso and Levania. |
clinical reasoning; cognitive bias; debiasing strategy; dual process theory; forensic psychiatry; hypothetico-deductive model; illness-script theory; psychomedicolegal analysis |
clinical reasoning; cognitive bias; court; forensic psychiatry; human; mental capacity; practice guideline; psychiatrist; review; theoretical study; training |
Frontiers Media S.A. |
16640640 |
|
|
Review |
Q1 |
1363 |
2668 |
|
|
|
273 |
Wibowo H., Harbuwono D.S., Tahapary D.L., Kartika R., Pradipta S., Larasati R.A. |
57217690943;36056341600;55944492500;57216548032;57212562643;57212549714; |
Impact of Sodium Butyrate Treatment in LPS-Stimulated Peripheral Blood Mononuclear Cells of Poorly Controlled Type 2 DM |
2021 |
Frontiers in Endocrinology |
12 |
|
652942 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112435096&doi=10.3389%2ffendo.2021.652942&partnerID=40&md5=351393601155dbe575078ee467f93e21 |
Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Division of Metabolic Endocrinology and Diabetes, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Integrated Laboratory, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Biomedicines, Faculty of Medicine, Universitas Muhammadiyah Jakarta, Jakarta, Indonesia |
Wibowo, H., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Harbuwono, D.S., Division of Metabolic Endocrinology and Diabetes, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Tahapary, D.L., Division of Metabolic Endocrinology and Diabetes, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Kartika, R., Division of Metabolic Endocrinology and Diabetes, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Pradipta, S., Integrated Laboratory, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Larasati, R.A., Department of Biomedicines, Faculty of Medicine, Universitas Muhammadiyah Jakarta, Jakarta, Indonesia |
Type 2 diabetes mellitus (T2DM) is associated with chronic low-grade inflammation, which is marked by the dysregulation of innate and adaptive immune responses. Therefore, reducing inflammation, possibly through an immunoregulatory agent, may play a role in T2DM treatment. Butyrate is the most potent short-chain fatty acid (SCFA), and it exerts anti-inflammatory properties by inhibiting histone deacetylase activity. As an immunoregulatory agent, sodium butyrate can inhibit nuclear factor kB (NF-kB) activation and reduce the production of pro-inflammatory cytokines in immune cells. The aim of the study was to measure the level of plasma butyrate in poorly controlled T2DM and normoglycemic participants and to compare the response of peripheral blood mononuclear cells (PBMCs) to sodium butyrate treatment between the groups by measuring production of the following cytokines: tumor necrosis factor (TNF)-α, interleukin (IL)-6, interferon (IFN)-γ, IL-13, and IL-10. The in vitro study examined the PBMCs of 15 participants with poorly controlled T2DM and 15 normoglycemic participants. PBMCs were cultured with the following stimulations for two days at a temperature of 37°C and 5% CO2: 100 ng/mL lipopolysaccharide (LPS), 1 mM sodium butyrate, or a combination of 100 ng/mL LPS and 1 mM sodium butyrate. Plasma butyrate was measured using gas chromatography-mass spectrometry, and cytokines from culture supernatant were analyzed using magnetic beads multiplex assay. Plasma butyrate levels in participants with poorly controlled T2DM did not significantly differ from those in normoglycemic participants (p = 0.105). Compared to treatment with an LPS-stimulated PBMC culture, treatment with 1 mM sodium butyrate reduced the levels of TNF-α (p < 0.039) and IFN-γ (p < 0.038) in normoglycemic participants. The same general trend was seen in PBMC from participants with poorly controlled T2DM, but higher variability appeared to preclude statistical significance. These data suggest that butyrate may modulate inflammatory cytokine production in human PBMCs, but more research is needed to determine if butyrate is anti-inflammatory in poorly controlled T2DM. © Copyright © 2021 Wibowo, Harbuwono, Tahapary, Kartika, Pradipta and Larasati. |
butyrate; inflammatory response; lipopolysaccharide (LPS); peripheral blood mononuclear cells; poorly controlled type 2 diabetes mellitus |
|
Frontiers Media S.A. |
16642392 |
|
|
Article |
Q1 |
1518 |
2233 |
|
|
|
282 |
Lazarus G., Wangsaputra V.K., Christianto, Louisa M., Soetikno V., Hamers R.L. |
57214599425;57215576000;57223348000;41461551400;36769252100;23034345900; |
Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials |
2021 |
Frontiers in Pharmacology |
12 |
|
664875 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111311631&doi=10.3389%2ffphar.2021.664875&partnerID=40&md5=708eaf175b9ad89a98ff6679c222f1c7 |
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom |
Lazarus, G., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Wangsaputra, V.K., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Christianto, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Louisa, M., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Soetikno, V., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Hamers, R.L., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom |
Objectives: To investigate the safety and pharmacokinetic profiles of long-acting injectable pre-exposure prophylaxis (LAI PrEP), notably cabotegravir (CAB-LA) and rilpivirine (RPV-LA), for the prevention of human immunodeficiency virus-1 (HIV-1) infection. Methods: Eligible randomized trials of LAI PrEP in HIV-uninfected and/or healthy patients were included and assessed with the Revised Cochrane risk-of-bias tool for randomized trials. Where feasible, a meta-analysis was performed for safety outcomes by using a random-effects model with risk ratios and their 95% confidence intervals as the common effect measure. The protocol was registered with PROSPERO CRD42020154772. Results: Eight studies cumulating a total of 666 participants were included in this systematic review, including five (362 intervention-arm volunteers) and four trials (194 intervention-arm volunteers) that investigated CAB-LA and RPV-LA, respectively. We found that both CAB-LA and RPV-LA were generally well-tolerated as their safety profiles were similar to placebo in terms of any adverse event (AE), serious AE, and AE-related withdrawals. Furthermore, pharmacokinetic analyses revealed favorable prospects in viral inhibitory activity of CAB-LA and RPV-LA. Intramuscular (IM) injection of CAB-LA 600 mg Q8W was superior to CAB-LA 800 mg Q12W in male participants, while the same was true for RPV-LA 1200 mg IM Q8W over other dosing regimens. Although these results are promising, further research is required to confirm the findings on RPV-LA as current evidence is limited. Conclusion: CAB-LA and RPV-LA have promising safety and pharmacokinetic profiles. The preventive efficacy of these agents is being evaluated in Phase 3 trials. © Copyright © 2021 Lazarus, Wangsaputra, Christianto, Louisa, Soetikno and Hamers. |
cabotegravir; HIV-human immunodeficiency virus; long acting injectable (LAI); pre-exposure (PrEP) prophylaxis; rilpivirine |
|
Frontiers Media S.A. |
16639812 |
|
|
Review |
Q1 |
1384 |
2619 |
|
|
|
303 |
Samara T., Wibowo H., Liem I., Prijanti A., Andrijono A. |
57208256339;57217690943;55802927800;57190863386;57208264133; |
Cullin 1 as a proangiogenic factor and its relationship with vascular endothelial growth factor and p21 are associated with the length of gestational age of pre-eclampsia |
2021 |
Journal of Natural Science, Biology and Medicine |
12 |
2 |
|
140 |
144 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111296351&doi=10.4103%2fjnsbm.JNSBM-123-20&partnerID=40&md5=10efc582ba2ed72d7813100c2ebbc2d5 |
Department of Biomedical Science, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Anatomy, Faculty of Medicine, Trisakti University, Jakarta, Indonesia; Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Obstetrics and Gynaecology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Samara, T., Department of Biomedical Science, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Anatomy, Faculty of Medicine, Trisakti University, Jakarta, Indonesia; Wibowo, H., Department of Biomedical Science, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Liem, I., Department of Biomedical Science, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Prijanti, A., Department of Biomedical Science, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Andrijono, A., Department of Biomedical Science, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Obstetrics and Gynaecology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Background: Cullin 1 (CUL1), vascular endothelial growth factor (VEGF), and p21 are proteins that play a role in pregnancy. CUL1 and VEGF are proangiogenic factors, whereas p21 is an antiangiogenic factor. An imbalance between proangiogenic and antiangiogenic factors is one of the various factors that cause pre-eclampsia (PE). The aim of this study was to analyze CUL1 levels in the relationship with VEGF levels and p21 levels based on gestational age at delivery in PE. Materials and Methods: This was a cross-sectional study of 70 placentas from PE patients divided in two groups of gestational age at delivery: <34 weeks and ≥34 weeks. Levels of CUL1, VEGF, and p21 were examined by the enzyme-linked immunosorbent assay technique. Statistical analysis was assessed by Spearman correlation test and Chi-square test, with a significant P < 0.05. Results: Low levels of CUL1 and low levels of VEGF were related with <34 weeks of gestational age at delivery, whereas high levels of CUL1 and high levels VEGF were related with ≥34 weeks of gestational age at delivery. There was a negative correlation between the high ratios of p21/CUL1 and <34 weeks of gestational age at delivery in PE. Conclusions: Low levels of CUL1 and low levels VEGF and high ratios of p21/CUL1 were associated with <34 weeks of gestational age at delivery in PE. © 2021 Wolters Kluwer Medknow Publications. All rights reserved. |
Cullin 1; gestational age; p21; pre-eclampsia; vascular endothelial growth factor |
|
Wolters Kluwer Medknow Publications |
09769668 |
|
|
Article |
Q3 |
236 |
17374 |
|
|
|
315 |
Purnomo G.A., Mitchell K.J., O’connor S., Kealy S., Taufik L., Schiller S., Rohrlach A., Cooper A., Llamas B., Sudoyo H., Teixeira J.C., Tobler R. |
56262110300;55937278100;57192065848;57016654100;57225108034;57225091129;56674549200;57225849511;8695218700;6603548824;56290678400;55780763900; |
Mitogenomes reveal two major influxes of papuan ancestry across wallacea following the last glacial maximum and austronesian contact |
2021 |
Genes |
12 |
7 |
965 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109185551&doi=10.3390%2fgenes12070965&partnerID=40&md5=046fa96fdfa7683fb4a23714ea942197 |
Australian Centre for Ancient DNA, School of Biological Sciences, University of Adelaide, Adelaide, 5005, Australia; Genome Diversity and Diseases Laboratory, Eijkman Institute of Molecular Biology, Jakarta, 10430, Indonesia; ARC Centre of Excellence for Australian Biodiversity and Heritage, University of Adelaide, Adelaide, 5005, Australia; Archaeology and Natural History, School of Culture, History and Language, College of Asia and the Pacific, Australian National University, Canberra, 2601, Australia; ARC Centre of Excellence for Australian Biodiversity and Heritage, Australian National University, Canberra, 2601, Australia; Evolution of Cultural Diversity Initiative, Australian National University, Canberra, 2601, Australia; ARC Centre of Excellence for Mathematical and Statistical Frontiers, School of Mathematical Sciences, The University of Adelaide, Adelaide, 5005, Australia; Department of Archaeogenetics, Max Planck Institute for the Science of Human History, Jena, 07745, Germany; Blue Sky Genetics, P.O. Box 287, Adelaide, 5137, Australia; South Australian Museum, Adelaide, 5000, Australia; Environment Institute, University of Adelaide, Adelaide, 5005, Australia; National Centre for Indigenous Genomics, Australian National University, Canberra, 2601, Australia; Department of Medical Biology, Faculty of Medicine, University of Indonesia, Jakarta, 10430, Indonesia; Sydney Medical School, University of Sydney, Sydney, 2050, Australia |
Purnomo, G.A., Australian Centre for Ancient DNA, School of Biological Sciences, University of Adelaide, Adelaide, 5005, Australia, Genome Diversity and Diseases Laboratory, Eijkman Institute of Molecular Biology, Jakarta, 10430, Indonesia; Mitchell, K.J., Australian Centre for Ancient DNA, School of Biological Sciences, University of Adelaide, Adelaide, 5005, Australia, ARC Centre of Excellence for Australian Biodiversity and Heritage, University of Adelaide, Adelaide, 5005, Australia; O’connor, S., Archaeology and Natural History, School of Culture, History and Language, College of Asia and the Pacific, Australian National University, Canberra, 2601, Australia, ARC Centre of Excellence for Australian Biodiversity and Heritage, Australian National University, Canberra, 2601, Australia; Kealy, S., Archaeology and Natural History, School of Culture, History and Language, College of Asia and the Pacific, Australian National University, Canberra, 2601, Australia, ARC Centre of Excellence for Australian Biodiversity and Heritage, Australian National University, Canberra, 2601, Australia, Evolution of Cultural Diversity Initiative, Australian National University, Canberra, 2601, Australia; Taufik, L., Genome Diversity and Diseases Laboratory, Eijkman Institute of Molecular Biology, Jakarta, 10430, Indonesia; Schiller, S., ARC Centre of Excellence for Mathematical and Statistical Frontiers, School of Mathematical Sciences, The University of Adelaide, Adelaide, 5005, Australia; Rohrlach, A., ARC Centre of Excellence for Mathematical and Statistical Frontiers, School of Mathematical Sciences, The University of Adelaide, Adelaide, 5005, Australia, Department of Archaeogenetics, Max Planck Institute for the Science of Human History, Jena, 07745, Germany; Cooper, A., Blue Sky Genetics, P.O. Box 287, Adelaide, 5137, Australia, South Australian Museum, Adelaide, 5000, Australia; Llamas, B., Australian Centre for Ancient DNA, School of Biological Sciences, University of Adelaide, Adelaide, 5005, Australia, ARC Centre of Excellence for Australian Biodiversity and Heritage, University of Adelaide, Adelaide, 5005, Australia, Environment Institute, University of Adelaide, Adelaide, 5005, Australia, National Centre for Indigenous Genomics, Australian National University, Canberra, 2601, Australia; Sudoyo, H., Genome Diversity and Diseases Laboratory, Eijkman Institute of Molecular Biology, Jakarta, 10430, Indonesia, Department of Medical Biology, Faculty of Medicine, University of Indonesia, Jakarta, 10430, Indonesia, Sydney Medical School, University of Sydney, Sydney, 2050, Australia; Teixeira, J.C., Australian Centre for Ancient DNA, School of Biological Sciences, University of Adelaide, Adelaide, 5005, Australia, ARC Centre of Excellence for Australian Biodiversity and Heritage, University of Adelaide, Adelaide, 5005, Australia, Evolution of Cultural Diversity Initiative, Australian National University, Canberra, 2601, Australia; Tobler, R., Australian Centre for Ancient DNA, School of Biological Sciences, University of Adelaide, Adelaide, 5005, Australia, ARC Centre of Excellence for Australian Biodiversity and Heritage, University of Adelaide, Adelaide, 5005, Australia, Evolution of Cultural Diversity Initiative, Australian National University, Canberra, 2601, Australia |
The tropical archipelago of Wallacea contains thousands of individual islands interspersed between mainland Asia and Near Oceania, and marks the location of a series of ancient oceanic voyages leading to the peopling of Sahul—i.e., the former continent that joined Australia and New Guinea at a time of lowered sea level—by 50,000 years ago. Despite the apparent deep antiquity of human presence in Wallacea, prior population history research in this region has been hampered by patchy archaeological and genetic records and is largely concentrated upon more recent history that follows the arrival of Austronesian seafarers ~3000–4000 years ago (3–4 ka). To shed light on the deeper history of Wallacea and its connections with New Guinea and Australia, we performed phylogeographic analyses on 656 whole mitogenomes from these three regions, including 186 new samples from eight Wallacean islands and three West Papuan populations. Our results point to a surprisingly dynamic population history in Wallacea, marked by two periods of extensive demographic change concentrated around the Last Glacial Maximum ~15 ka and post-Austronesian contact ~3 ka. These changes appear to have greatly diminished genetic signals informative about the original peopling of Sahul, and have important implications for our current understanding of the population history of the region. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. |
Human migrations; Mitochondria; MtDNA; Phylogeography; Sahul |
mitochondrial DNA; ancestry group; Article; Asia; Australia; Austronesian people; biogeographic region; gene sequence; haplotype; human; last glacial maximum; migration; mitochondrial genome; Papua New Guinea; Philippines; phylogeny; phylogeography; polymerase chain reaction; population size; population structure; sailor; sequence alignment; simulation; Wallacea; animal; archeology; beetle; female; genetics; history; male; mitochondrial genome; Pacific islands; phylogeny; phylogeography; population genetics; Animals; Archaeology; Asia; Australia; Coleoptera; Female; Genetics, Population; Genome, Mitochondrial; Haplotypes; History, Ancient; Humans; Male; New Guinea; Oceania; Phylogeny; Phylogeography |
MDPI |
20734425 |
|
34202821 |
Article |
Q2 |
1337 |
2737 |
|
|
|
397 |
Siste K., Hanafi E., Sen L.T., Murtani B.J., Christian H., Limawan A.P., Siswidiani L.P., Adrian |
55644113100;56737010600;57219034101;57216652176;57209266195;57202712511;57219029296;57216932703; |
Implications of COVID-19 and Lockdown on Internet Addiction Among Adolescents: Data From a Developing Country |
2021 |
Frontiers in Psychiatry |
12 |
|
665675 |
|
|
|
6 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107077623&doi=10.3389%2ffpsyt.2021.665675&partnerID=40&md5=19567c64b9f1c1b25ae702d165f6737d |
Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia |
Siste, K., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Hanafi, E., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Sen, L.T., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Murtani, B.J., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Christian, H., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Limawan, A.P., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Siswidiani, L.P., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Adrian, Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia |
Introduction: Physical distancing policy during coronavirus disease 2019 (COVID-19) pandemic requires adolescents to spend most of their time at home, thus increasing Internet use duration. Limited social interaction with their peers may lead to loneliness and an increased risk of mental health among adolescents. This study aimed to assess the prevalence of Internet addiction (IA) among adolescents and analyze the influence of psychosocial factors toward the heightened risk of IA during the COVID-19 pandemic. Methods: An online survey comprising sociodemographic questionnaire, Internet Addiction Diagnostic Questionnaire (KDAI), Strengths and Difficulties Questionnaire (SDQ), and Pittsburgh Sleep Quality Index (PSQI) was distributed. Overall, a total of 2,932 adolescents (mean age, 17.38 ± 2.24 years old; female, 78.7%), originating from 33 of 34 provinces in Indonesia, completed the survey. Results: The point prevalence of IA among Indonesian adolescents during the COVID-19 outbreak was 19.3%. Increased Internet use duration, internalization, externalization, low prosocial behavior, and sleep disturbances were found as risk factors of IA, either directly or as mediating variables. Physical distancing, large-scale social restriction (PSBB), and health status were not correlated to IA. Discussion: Physical distancing was not established as a risk of IA. This could be due to other psychological factors such as internalization, externalization, prosocial, and sleep problems that had correlations to IA occurrence among adolescents in the COVID-19 pandemic. Sleep impairment might have resulted from the emotional and behavioral issues and directly contributed to IA development. Conclusion: The present study found the prevalence of IA among Indonesian adolescents to be higher than the adult during the COVID-19 pandemic. Several psychological measures were indicated to increase the risk of IA, while physical distancing did not elevate the risk. Thus, remote schooling is preferable in Indonesia along with proper parental supervision to minimize Internet use for entertainment purposes. © Copyright © 2021 Siste, Hanafi, Sen, Murtani, Christian, Limawan, Siswidiani and Adrian. |
adolescents; coronavirus disease 2019; Indonesia; internet addiction; lockdown; physical distancing; psychopathology; sleep quality |
adolescent; adolescent disease; age distribution; Article; behavior disorder; controlled study; coronavirus disease 2019; demography; developing country; emotional disorder; externalization (behavior); female; health status; health survey; human; Indonesia; Indonesian; internalization (behavior); internet addiction; Internet Addiction Diagnostic Questionnaire; major clinical study; male; national lockdown; pandemic; Pittsburgh Sleep Quality Index; prevalence; prosocial behavior; psychological aspect; questionnaire; risk assessment; sex ratio; sleep disorder; social aspect; social distancing; social psychology; strengths and difficulties questionnaire |
Frontiers Media S.A. |
16640640 |
|
|
Article |
Q1 |
1363 |
2668 |
|
|
|
426 |
Radfar S.R., De Jong C.A.J., Farhoudian A., Ebrahimi M., Rafei P., Vahidi M., Yunesian M., Kouimtsidis C., Arunogiri S., Massah O., Deylamizadeh A., Brady K.T., Busse A., Potenza M.N., Ekhtiari H., Baldacchino A.M., Abagiu A.O., Abouna F.D.N., Ahmed M.H., Al-ansari B., Mahmmoud Abu Al-khair F., Almaqbali M.H., Ambekar A., Ardabili H.M., Arya S., Lasebikan V.O., Ayasreh M.A., Basu D., Benmebarek Z., Bhad R., Blaise M., Bonnet N., Brasch J., Broers B., Butner J.L., Camilleri M., Campello G., Carra G., Celic I., Chalabianloo F., Chaturvedi A., de Jesús Eduardo Noyola Cherpitel J., Clark K.J., Cyders M.A., de Bernardis E., Derry J.E., Dhagudu N.K., Dolezalova P., Dom G., Dunlop A.J., Elhabiby M.M., Elkholy H., Essien N.F., Farah G.I., Ferri M., Floros G.D., Friedman C., Fuderanan C.H., Gerra G., Ghosh A., Gogia M., Grammatikopoulos I.A., Grandinetti P., Guirguis A., Gutnisky D., Haber P.S., Hassani-Abharian P., Hooshyari Z., Ibrahim I.I.M., Ieong H., Indradewi R.N., Iskandar S., Jain S., James S., Javadi S.M.H., Joe K.H., Jokubonis D., Jovanova A.T., Kamal R.M., Kantchelov A.I., Kathiresan P., Katzman G., Kawale P., Kern A.M., Kessler F.H.P., Kim S., Kimball A.M., Kljucevic Z., Siste K., Lev R., Lee H.K., Lengvenyte A., Lev-ran S., Mabelya G.S., Mahi M.A.E., Maphisa J., Maremmani I., Masferrer L., McCambridge O., McGovern G.G., Min A.K., Moghanibashi-Mansourieh A., Mora-Rios J., Mudalige I.U.K., Mukherjee D., Munira P.M., Myers B., Menon T N J., Narasimha V.L., Ndionuka N., Nejatisafa A., Niaz K., Nizami A.T., Nuijens J.H., Orsolini L., Oum V., Oyemade A.A., Palavra I.R., Pant S.B., Paredes J., Peyron E., Alberto Quirós R., Qurishi R., Rafiq N.U.Z., Rao R.R., Ratta-apha W., Raymond K., Reimer J., Renaldo E., Rezapour T., Robertson J.R., Roncero C., Roub F., Rubenstein E.J., Rupp C.I., Saenz E., Salehi M., Samartzis L., Sarubbo L.B., Segrec N., Shah B., Shen H., Shirasaka T., Shoptaw S., Sintango F.M., Sosa V.A., Subata E., Sztycberg N., Taghizadeh F., Teck J., Tjagvad C., Torrens M., Twala J.M., Vadivel R., Volpicelli J.R., Weijs J., Wintoniw S.M., Wittayanookulluk A., Wojnar M., Yasir S., Yitayih Y., Zhao M., Zonoozi A.K., ISAM-PPIG Global Survey Consortium |
36019651400;55394697400;25631625900;57218203004;57218199674;57203060812;14622058700;6602323007;55912287400;57044778200;57221410258;7101818468;57196510693;7006591634;26632924600;6603786612;55021572500;57221605725;57221411272;56996118200;57223918710;57221411355;35749590300;55658200400;35463222300;8344788700;57221410448;18833291700;57219202850;55789741800;6603894892;15135243700;57189041459;7003868723;56816710600;57221410155;56400851700;7003818736;24176502200;26026739900;54936844000;57221594973;57221410761;6504408224;55604104700;57221409824;57203836122;6603422138;12768470700;57219674374;26767656700;55086535500;57191041815;57221411550;8871569800;12768168000;57221411410;57210375852;55578764500;36833820900;57205763778;27367905800;55487378900;55496109900;57221411047;7004422180;54892046900;36607951600;57216708013;57193806115;57221410095;37004580200;57207211289;57216621884;57207842636;15062725000;57188646762;57221411023;57225330134;24468101500;57023935300;57221410517;55928375400;55031071400;57202970264;57221410531;35420584800;57203155640;55644113100;8913859800;8600274900;57189340754;23019092700;57221410613;57223919852;57200792839;7003948428;6507438528;56527137000;57221410507;57221411329;56059054800;6506077151;57214574855;57197364393;57221410358;7202684194;57202980793;56272241600;57221410263;55666521300;57194102646;12144358600;7004198198;55376767200;57217227990;16234058300;57225265059;36114863900;57221411223;57205355338;57223921125;55735687800;57221410341;57221411320;35604346900;56783754400;56000939600;57221410809;56968163500;57205640157;7003524112;57191926633;57221411128;7006106435;26656074800;56400278400;36633076300;57221409908;24476669600;57219874143;57216762422;7005625709;7003465287;57221409902;57221409982;56616079200;57221410011;55802145800;57212685292;57188537200;57202041764;57221411350;57219874702;57209053124;57221410085;57221410695;55151590700;6701757799;57221410275;57204013732;55185317400;57218205554; |
Reorganization of Substance Use Treatment and Harm Reduction Services During the COVID-19 Pandemic: A Global Survey |
2021 |
Frontiers in Psychiatry |
12 |
|
639393 |
|
|
|
14 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106509698&doi=10.3389%2ffpsyt.2021.639393&partnerID=40&md5=1fea38b85d8c747702486edae8c470b9 |
Department of Neuroscience and Addiction, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, Tehran, Iran; Integrated Substance Abuse Programs Department, University of California, Los Angeles, Los Angeles, CA, United States; Behavioral Science Institute Radboud University, Nijmegen, Netherlands; Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran; Materials and Energy Research Center, Tehran, Iran; Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran; Department of Psychology, Faculty of Psychology and Education, University of Tehran, Tehran, Iran; School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; Surrey and Borders Partnership, NHS Foundation Trust, Leatherhead, United Kingdom; Turning Point, Eastern Health, Box Hill, VIC, Australia; Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran; Rebirth Charity Society NGO, Tehran, Iran; Medical University of South Carolina, Charleston, SC, United States; Drug Prevention and Health Branch, Division for Operations, United States; Connecticut Council on Problem Gambling, Connecticut Mental Health Center, Yale School of Medicine, New Haven, CT, United States; Laureate Institute for Brain Research, Tulsa, OK, United States; School of Medicine, University of St Andrews, St Andrews, United Kingdom; Office on Drugs and Crime, Vienna, Austria; Prof. Dr. Matei Bals- Arena OMT Department, National Institute for Infectious Diseases, Bucharest, Romania; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon; Alamal psychiatric hospital, Dubai, United Arab Emirates; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Al Ahliyya Amman University, Amman, Jordan; Ministry of Health, Muscat, Oman; Department of Psychiatry and National Drug Dependence Treatment Center (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India; Faculty of Medicine, Psychiatry and Behavioral Sciences Research Center, Ibn-e-Sina Hospital, Mashhad University of Medical Sciences, Mashhad, Iran; State Drug Dependence Treatment Center, Institute of Mental Health, Pt BDS University of Health Sciences, Rohtak, India; Department of Psychiatry, College of Medicine, University of Ibadan, Ibadan, Nigeria; Addiction medicine clinic, Amman, Jordan; Department of Psychiatry, Drug De-addiction & Treatment Center, Postgraduate Institute of Medical Education & Research, Chandigarh, India; Addiction medicine clinic, Mila, Algeria; Center medical Marmottan, Paris, France; Réseau de Prévention des Addictions (RESPADD), Paris, France; Department of Psychiatry and Behavioral Neurosciences, Michael DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada; Geneva University Hospitals, Geneva, Switzerland; CUNY School of Medicine, New York, NY, United States; Aġenzija Sedqa, Santa Venera, Malta; United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Department of Medicine and Surgery, University Milan-Bicocca, Milan, Italy; University Psychiatric Hospital Vrapce, Zagreb, Croatia; Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway; Department of Biochemistry, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal, India; Addiction medicine clinic, Mexico City, Mexico; Addiction Crisis Solutions, Louisville, KY, United States; Department of Psychology, Indiana University Purdue University - Indianapolis, Indianapolis, IN, United States; SerT Lentini, ASP Siracusa, Syracuse, Italy; Serenity Vista Addiction Treatment Center, Jaramillo, Panama; Department of Psychiatry, ESIC Medical College, Hyderabad, India; National Institute of Mental Health, Klecany, Czech Republic; Collaborative Antwerp Psychiatric Research Institute (CAPRI), Antwerp University (UA), Antwerp, Belgium; Drug & Alcohol Clinical Services, Hunter New England Local Health District, New Lambton, NSW, Australia; Ain Shams University, Cairo, Egypt; Department of Neurology and Psychiatry, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Center for Research and Information on Substance Abuse, Jos, Nigeria; Addiction Medicine Clinic, Damascus, Syrian Arab Republic; European Monitoring Center for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal; 2nd Department of Psychiatry, Aristotle University of Thessaloniki, Thessaloniki, Greece; Brown University and Lifespan Health System, Providence, RI, United States; Fuderanan Mental Health Clinic, Manila, Philippines; Georgian Harm Reduction Network, Tbilisi, Georgia; Organization Against Drugs, Primary Care Health Center, Veria, Greece; Addictions Services (Ser.D.), Department of Territorial Assistance, ASL Teramo, Teramo, Italy; Swansea University Medical School, Institute of Life Sciences 2, Sketty, United Kingdom; Hospital Borda, Universidad de Buenos Aires, Buenos Aires, Argentina; University of Sydney, Sydney, NSW, Australia; Institutes for Cognitive Science Studies (IRICSS), Brain and Cognition Clinic, Tehran, Iran; Tehran University of Medical Sciences, Tehran, Iran; Department of Anesthesiology, Yale University, New Haven, CT, United States; Drugs Rehabilitation Center, National Narcotics Board of Indonesia, East Jakarta, Indonesia; Department of Psychiatry, Universitas Padjadjaran, Bandung, Indonesia; Department of Psychiatry, Heritage Institute of Medical Sciences (HIMS), Varanasi, India; Univeristi Malaysia Sabah, Sabah, Malaysia; Department of Social Work, University of Social Welfare & Rehabilitation Sciences, Tehran, Iran; National Center for Mental Health of Korea, Seoul, South Korea; Republican Center for Addictive Disorders, Vilnius, Lithuania; Addiction medicine clinic, Skopje, North Macedonia; Naufar Institute, Doha, Qatar; The Kantchelov Clinic, Sofia, Bulgaria; Mount Sinai Medical Center, New York, NY, United States; African Institute for Development Policy, Lilongwe, Malawi; Sobriety Centers of New Hampshire, Antrim, NH, United States; Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Department of Neuropsychiatry, Pusan National University Yangsan Hospital, Yangsan, South Korea; Chatham House, Washington, United States; Institute for Public Health of Split-Dalmatia County, Split, Croatia; Faculty of Medicine, Universitas Indonesia-Ciptomangunkusumo Hospital, Jakarta, Indonesia; Scripps Mercy Hospital, San Diego, CA, United States; Department of Psychiatry, The Catholic University of Korea, Seoul, South Korea; Faculty of Medicine, Institute of Clinical Medicine, Psychiatric Clinic, Vilnius University, Vilnius, Lithuania; Tel Aviv University, Tel Aviv, Israel; Israel Center on Addiction, Netanya, Israel; Community Health Work, Dar es Salaam, Tanzania; Hayat Center for Treatment and Psycho-social Rehabilitation, Khartoum, Sudan; University of Botswana, Gaborone, Botswana; V.P. Dole, Dual Disorder Unit, Santa Chiara University Hospital, University of Pisa, Pisa, Italy; CAS Girona, Department of Psychology, University of Girona, Girona, Spain; Community addiction team, Southern Health and Social Care Trust, Craigavon, United Kingdom; Priority Medical Clinic, Dublin, Ireland; Save the Children International, Yangon, Myanmar; Dirección de Investigaciones Epidemiológicas y Sociales, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico; Department of Psychiatry, Faculty of Medicine, Sir John Kotelawala Defense University, Colombo, Sri Lanka; Center for Addiction Medicine, NIMHANS, Bangalore, India; Kleopatra Kodric, Irena Nisic, Ljubljana, Slovenia; Alcohol Tobacco and Other Drug Research Unit, South African Medical Research Council, Cape Town, South Africa; NIMHANS, Bangalore, India; Department of Psychiatry, Center for Addiction Medicine, National Institute of Mental Health and Neurosciences, Bengaluru, India; Federal Neuropsychiatric Hospital, Calabar, Nigeria; Department of Psychiatry, Psychosomatic Research Center, Tehran University of Medical Sciences, Tehran, Iran; Institute of Psychiatry, WHO Collaborating Center for Mental Health, Rawalpindi, Pakistan; Brijder Addiction Care, Zaandam, Netherlands; Department of Clinical Neurosciences/DIMSC, Unit of Clinical Psychiatry, School of Medicine, Polytechnic University of Marche, Ancona, Italy; Koh Kong Provincial Hospital, Phoumin, Cambodia; Kaiser Permanente, Oakland, CA, United States; Psychiatric hospital Sveti Ivan, Zagreb, Croatia; Department of Psychiatry and mental health, Institute of Medicine, Tribhuvan University, Kirtipur, Nepal; Universidad de El Salvador, San Salvador, El Salvador; AddiPsy, Lyon, France; Addiction medicine clinic, San José, Costa Rica; Novadic-Kentron Addiction Care Network, Vught, Netherlands; Phoenix Foundation for Research and Development, Lahore, Pakistan; Barwon Health, Geelong, VIC, Australia; Faculty of Medicine Siriraj Hospital, Mahidol University, Salaya, Thailand; University of the Sunshine Coast (USC), QueenslandQLD, Australia; Center for Interdisciplinary Addiction Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drugs Rehabilitation Center, National Narcotics Board of Indonesia, East Jakarta, Indonesia; Department of Cognitive Psychology, Institute for Cognitive Science Studies, Tehran, Iran; Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; Psychiatry Service, University of Salamanca Health Care Complex, School of Medicine, University of Salamanca, Salamanca, Spain; PGIMER, Chandigarh, India; Street Health Center, Kingston, ON, Canada; Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Department of Neurosciences and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran; Medical School, University of Cyprus, Cyprus; Clínica Psiquiátrica de la Facultad de Medicina, Uruguay; Center for Treatment of Drug addiction, University Psychiatric Clinic, Ljubljana, Slovenia; Department of Psychiatry, Patan Academy of Health Sciences, School of Medicine, Lagankhel, Nepal; Department of Psychiatry, Second Xiangya Hospital, Central South University, Changsha, China; Department of Psychiatry, Teine Keijinkai Medical Center, Sapporo, Hokkaido, Japan; Department of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States; Health Professions Councils of Namibia, Windhoek, Namibia; Addiction medicine clinic, Montevideo, Uruguay; Republican Center for Addictive Disorders, Vilnius, Lithuania; Asociasion Programa Andres Argentina, Santa Fe, Argentina; Mazandaran University of Medical Sciences, Mazandaran, Iran; MRC/CSO SPHSU, University of Glasgow, Glasgow, United Kingdom; Gladsaxe Substance Use Disorder Treatment Center, Gladsaxe, Denmark; Institut de Neuropsiquiatria i Addiccions, IMIM-Hospital del Mar, Medical Research, Barcelona, Spain; NACADA, Nairobi, Kenya; Waikato District Health Board (WDHB) Hamilton, Hamilton, New Zealand; Institute of Addiction Medicine, Plymouth Meeting, PA, United States; Jellinek, Amsterdam, Netherlands; Addictions Foundation of Manitoba, Manitoba, Canada; Thanyarak Chiangmai hospital, Khilek, Thailand; Medical University of Warsaw, Warsaw, Poland; Jimma University, Jimma, Ethiopia; Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran |
Radfar, S.R., Department of Neuroscience and Addiction, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, Tehran, Iran, Integrated Substance Abuse Programs Department, University of California, Los Angeles, Los Angeles, CA, United States; De Jong, C.A.J., Behavioral Science Institute Radboud University, Nijmegen, Netherlands; Farhoudian, A., Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran; Ebrahimi, M., Materials and Energy Research Center, Tehran, Iran, Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran; Rafei, P., Department of Psychology, Faculty of Psychology and Education, University of Tehran, Tehran, Iran; Vahidi, M., Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran; Yunesian, M., School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; Kouimtsidis, C., Surrey and Borders Partnership, NHS Foundation Trust, Leatherhead, United Kingdom; Arunogiri, S., Turning Point, Eastern Health, Box Hill, VIC, Australia; Massah, O., Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran; Deylamizadeh, A., Rebirth Charity Society NGO, Tehran, Iran; Brady, K.T., Medical University of South Carolina, Charleston, SC, United States; Busse, A., Drug Prevention and Health Branch, Division for Operations, United States, Office on Drugs and Crime, Vienna, Austria; Potenza, M.N., Connecticut Council on Problem Gambling, Connecticut Mental Health Center, Yale School of Medicine, New Haven, CT, United States; Ekhtiari, H., Laureate Institute for Brain Research, Tulsa, OK, United States; Baldacchino, A.M., School of Medicine, University of St Andrews, St Andrews, United Kingdom; Abagiu, A.O., Prof. Dr. Matei Bals- Arena OMT Department, National Institute for Infectious Diseases, Bucharest, Romania; Abouna, F.D.N., Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon; Ahmed, M.H., Alamal psychiatric hospital, Dubai, United Arab Emirates; Al-ansari, B., Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Mahmmoud Abu Al-khair, F., Al Ahliyya Amman University, Amman, Jordan; Almaqbali, M.H., Ministry of Health, Muscat, Oman; Ambekar, A., Department of Psychiatry and National Drug Dependence Treatment Center (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India; Ardabili, H.M., Faculty of Medicine, Psychiatry and Behavioral Sciences Research Center, Ibn-e-Sina Hospital, Mashhad University of Medical Sciences, Mashhad, Iran; Arya, S., State Drug Dependence Treatment Center, Institute of Mental Health, Pt BDS University of Health Sciences, Rohtak, India; Lasebikan, V.O., Department of Psychiatry, College of Medicine, University of Ibadan, Ibadan, Nigeria; Ayasreh, M.A., Addiction medicine clinic, Amman, Jordan; Basu, D., Department of Psychiatry, Drug De-addiction & Treatment Center, Postgraduate Institute of Medical Education & Research, Chandigarh, India; Benmebarek, Z., Addiction medicine clinic, Mila, Algeria; Bhad, R., Department of Psychiatry and National Drug Dependence Treatment Center (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India; Blaise, M., Center medical Marmottan, Paris, France; Bonnet, N., Réseau de Prévention des Addictions (RESPADD), Paris, France; Brasch, J., Department of Psychiatry and Behavioral Neurosciences, Michael DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada; Broers, B., Geneva University Hospitals, Geneva, Switzerland; Butner, J.L., CUNY School of Medicine, New York, NY, United States; Camilleri, M., Aġenzija Sedqa, Santa Venera, Malta; Campello, G., United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Carra, G., Department of Medicine and Surgery, University Milan-Bicocca, Milan, Italy; Celic, I., University Psychiatric Hospital Vrapce, Zagreb, Croatia; Chalabianloo, F., Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway; Chaturvedi, A., Department of Biochemistry, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal, India; de Jesús Eduardo Noyola Cherpitel, J., Addiction medicine clinic, Mexico City, Mexico; Clark, K.J., Addiction Crisis Solutions, Louisville, KY, United States; Cyders, M.A., Department of Psychology, Indiana University Purdue University - Indianapolis, Indianapolis, IN, United States; de Bernardis, E., SerT Lentini, ASP Siracusa, Syracuse, Italy; Derry, J.E., Serenity Vista Addiction Treatment Center, Jaramillo, Panama; Dhagudu, N.K., Department of Psychiatry, ESIC Medical College, Hyderabad, India; Dolezalova, P., National Institute of Mental Health, Klecany, Czech Republic; Dom, G., Collaborative Antwerp Psychiatric Research Institute (CAPRI), Antwerp University (UA), Antwerp, Belgium; Dunlop, A.J., Drug & Alcohol Clinical Services, Hunter New England Local Health District, New Lambton, NSW, Australia; Elhabiby, M.M., Ain Shams University, Cairo, Egypt; Elkholy, H., Department of Neurology and Psychiatry, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Essien, N.F., Center for Research and Information on Substance Abuse, Jos, Nigeria; Farah, G.I., Addiction Medicine Clinic, Damascus, Syrian Arab Republic; Ferri, M., European Monitoring Center for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal; Floros, G.D., 2nd Department of Psychiatry, Aristotle University of Thessaloniki, Thessaloniki, Greece; Friedman, C., Brown University and Lifespan Health System, Providence, RI, United States; Fuderanan, C.H., Fuderanan Mental Health Clinic, Manila, Philippines; Gerra, G., Geneva University Hospitals, Geneva, Switzerland; Ghosh, A., Department of Psychiatry, Drug De-addiction & Treatment Center, Postgraduate Institute of Medical Education & Research, Chandigarh, India; Gogia, M., Georgian Harm Reduction Network, Tbilisi, Georgia; Grammatikopoulos, I.A., Organization Against Drugs, Primary Care Health Center, Veria, Greece; Grandinetti, P., Addictions Services (Ser.D.), Department of Territorial Assistance, ASL Teramo, Teramo, Italy; Guirguis, A., Swansea University Medical School, Institute of Life Sciences 2, Sketty, United Kingdom; Gutnisky, D., Hospital Borda, Universidad de Buenos Aires, Buenos Aires, Argentina; Haber, P.S., University of Sydney, Sydney, NSW, Australia; Hassani-Abharian, P., Institutes for Cognitive Science Studies (IRICSS), Brain and Cognition Clinic, Tehran, Iran; Hooshyari, Z., Tehran University of Medical Sciences, Tehran, Iran; Ibrahim, I.I.M., Ain Shams University, Cairo, Egypt; Ieong, H., Department of Anesthesiology, Yale University, New Haven, CT, United States; Indradewi, R.N., Drugs Rehabilitation Center, National Narcotics Board of Indonesia, East Jakarta, Indonesia; Iskandar, S., Department of Psychiatry, Universitas Padjadjaran, Bandung, Indonesia; Jain, S., Department of Psychiatry, Heritage Institute of Medical Sciences (HIMS), Varanasi, India; James, S., Univeristi Malaysia Sabah, Sabah, Malaysia; Javadi, S.M.H., Department of Social Work, University of Social Welfare & Rehabilitation Sciences, Tehran, Iran; Joe, K.H., National Center for Mental Health of Korea, Seoul, South Korea; Jokubonis, D., Republican Center for Addictive Disorders, Vilnius, Lithuania; Jovanova, A.T., Addiction medicine clinic, Skopje, North Macedonia; Kamal, R.M., Naufar Institute, Doha, Qatar; Kantchelov, A.I., The Kantchelov Clinic, Sofia, Bulgaria; Kathiresan, P., Department of Psychiatry and National Drug Dependence Treatment Center (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi, India; Katzman, G., Mount Sinai Medical Center, New York, NY, United States; Kawale, P., African Institute for Development Policy, Lilongwe, Malawi; Kern, A.M., Sobriety Centers of New Hampshire, Antrim, NH, United States; Kessler, F.H.P., Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Kim, S., Department of Neuropsychiatry, Pusan National University Yangsan Hospital, Yangsan, South Korea; Kimball, A.M., Chatham House, Washington, United States; Kljucevic, Z., Institute for Public Health of Split-Dalmatia County, Split, Croatia; Siste, K., Faculty of Medicine, Universitas Indonesia-Ciptomangunkusumo Hospital, Jakarta, Indonesia; Lev, R., Scripps Mercy Hospital, San Diego, CA, United States; Lee, H.K., Department of Psychiatry, The Catholic University of Korea, Seoul, South Korea; Lengvenyte, A., Faculty of Medicine, Institute of Clinical Medicine, Psychiatric Clinic, Vilnius University, Vilnius, Lithuania; Lev-ran, S., Tel Aviv University, Tel Aviv, Israel, Israel Center on Addiction, Netanya, Israel; Mabelya, G.S., Community Health Work, Dar es Salaam, Tanzania; Mahi, M.A.E., Hayat Center for Treatment and Psycho-social Rehabilitation, Khartoum, Sudan; Maphisa, J., University of Botswana, Gaborone, Botswana; Maremmani, I., V.P. Dole, Dual Disorder Unit, Santa Chiara University Hospital, University of Pisa, Pisa, Italy; Masferrer, L., CAS Girona, Department of Psychology, University of Girona, Girona, Spain; McCambridge, O., Community addiction team, Southern Health and Social Care Trust, Craigavon, United Kingdom; McGovern, G.G., Priority Medical Clinic, Dublin, Ireland; Min, A.K., Save the Children International, Yangon, Myanmar; Moghanibashi-Mansourieh, A., National Center for Mental Health of Korea, Seoul, South Korea; Mora-Rios, J., Dirección de Investigaciones Epidemiológicas y Sociales, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico; Mudalige, I.U.K., Department of Psychiatry, Faculty of Medicine, Sir John Kotelawala Defense University, Colombo, Sri Lanka; Mukherjee, D., Center for Addiction Medicine, NIMHANS, Bangalore, India; Munira, P.M., Kleopatra Kodric, Irena Nisic, Ljubljana, Slovenia; Myers, B., Alcohol Tobacco and Other Drug Research Unit, South African Medical Research Council, Cape Town, South Africa; Menon T N, J., NIMHANS, Bangalore, India; Narasimha, V.L., Department of Psychiatry, Center for Addiction Medicine, National Institute of Mental Health and Neurosciences, Bengaluru, India; Ndionuka, N., Federal Neuropsychiatric Hospital, Calabar, Nigeria; Nejatisafa, A., Department of Psychiatry, Psychosomatic Research Center, Tehran University of Medical Sciences, Tehran, Iran; Niaz, K., United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Nizami, A.T., Institute of Psychiatry, WHO Collaborating Center for Mental Health, Rawalpindi, Pakistan; Nuijens, J.H., Brijder Addiction Care, Zaandam, Netherlands; Orsolini, L., Department of Clinical Neurosciences/DIMSC, Unit of Clinical Psychiatry, School of Medicine, Polytechnic University of Marche, Ancona, Italy; Oum, V., Koh Kong Provincial Hospital, Phoumin, Cambodia; Oyemade, A.A., Kaiser Permanente, Oakland, CA, United States; Palavra, I.R., Psychiatric hospital Sveti Ivan, Zagreb, Croatia; Pant, S.B., Department of Psychiatry and mental health, Institute of Medicine, Tribhuvan University, Kirtipur, Nepal; Paredes, J., Universidad de El Salvador, San Salvador, El Salvador; Peyron, E., AddiPsy, Lyon, France; Alberto Quirós, R., Addiction medicine clinic, San José, Costa Rica; Qurishi, R., Novadic-Kentron Addiction Care Network, Vught, Netherlands; Rafiq, N.U.Z., Phoenix Foundation for Research and Development, Lahore, Pakistan; Rao, R.R., Barwon Health, Geelong, VIC, Australia; Ratta-apha, W., Faculty of Medicine Siriraj Hospital, Mahidol University, Salaya, Thailand; Raymond, K., University of the Sunshine Coast (USC), QueenslandQLD, Australia; Reimer, J., Center for Interdisciplinary Addiction Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Renaldo, E., Drugs Rehabilitation Center, National Narcotics Board of Indonesia, East Jakarta, Indonesia; Rezapour, T., Department of Cognitive Psychology, Institute for Cognitive Science Studies, Tehran, Iran; Robertson, J.R., Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; Roncero, C., Psychiatry Service, University of Salamanca Health Care Complex, School of Medicine, University of Salamanca, Salamanca, Spain; Roub, F., PGIMER, Chandigarh, India; Rubenstein, E.J., Street Health Center, Kingston, ON, Canada; Rupp, C.I., Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Saenz, E., United Nations Office on Drugs and Crime (UNODC), Vienna, Austria; Salehi, M., Department of Neurosciences and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran; Samartzis, L., Medical School, University of Cyprus, Cyprus; Sarubbo, L.B., Clínica Psiquiátrica de la Facultad de Medicina, Uruguay; Segrec, N., Center for Treatment of Drug addiction, University Psychiatric Clinic, Ljubljana, Slovenia; Shah, B., Department of Psychiatry, Patan Academy of Health Sciences, School of Medicine, Lagankhel, Nepal; Shen, H., Department of Psychiatry, Second Xiangya Hospital, Central South University, Changsha, China; Shirasaka, T., Department of Psychiatry, Teine Keijinkai Medical Center, Sapporo, Hokkaido, Japan; Shoptaw, S., Department of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States; Sintango, F.M., Health Professions Councils of Namibia, Windhoek, Namibia; Sosa, V.A., Addiction medicine clinic, Montevideo, Uruguay; Subata, E., Republican Center for Addictive Disorders, Vilnius, Lithuania; Sztycberg, N., Asociasion Programa Andres Argentina, Santa Fe, Argentina; Taghizadeh, F., Mazandaran University of Medical Sciences, Mazandaran, Iran; Teck, J., MRC/CSO SPHSU, University of Glasgow, Glasgow, United Kingdom; Tjagvad, C., Gladsaxe Substance Use Disorder Treatment Center, Gladsaxe, Denmark; Torrens, M., Institut de Neuropsiquiatria i Addiccions, IMIM-Hospital del Mar, Medical Research, Barcelona, Spain; Twala, J.M., NACADA, Nairobi, Kenya; Vadivel, R., Waikato District Health Board (WDHB) Hamilton, Hamilton, New Zealand; Volpicelli, J.R., Institute of Addiction Medicine, Plymouth Meeting, PA, United States; Weijs, J., Jellinek, Amsterdam, Netherlands; Wintoniw, S.M., Addictions Foundation of Manitoba, Manitoba, Canada; Wittayanookulluk, A., Thanyarak Chiangmai hospital, Khilek, Thailand; Wojnar, M., Medical University of Warsaw, Warsaw, Poland; Yasir, S., Institute of Psychiatry, WHO Collaborating Center for Mental Health, Rawalpindi, Pakistan; Yitayih, Y., Jimma University, Jimma, Ethiopia; Zhao, M., Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Zonoozi, A.K., Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; ISAM-PPIG Global Survey Consortium |
Background: The coronavirus disease 2019 (COVID-19) pandemic has impacted people with substance use disorders (SUDs) worldwide, and healthcare systems have reorganized their services in response to the pandemic. Methods: One week after the announcement of the COVID-19 as a pandemic, in a global survey, 177 addiction medicine professionals described COVID-19-related health responses in their own 77 countries in terms of SUD treatment and harm reduction services. The health responses were categorized around (1) managerial measures and systems, (2) logistics, (3) service providers, and (4) vulnerable groups. Results: Respondents from over 88% of countries reported that core medical and psychiatric care for SUDs had continued; however, only 56% of countries reported having had any business continuity plan, and 37.5% of countries reported shortages of methadone or buprenorphine supplies. Participants of 41% of countries reported partial discontinuation of harm-reduction services such as needle and syringe programs and condom distribution. Fifty-seven percent of overdose prevention interventions and 81% of outreach services were also negatively impacted. Conclusions: Participants reported that SUD treatment and harm-reduction services had been significantly impacted globally early during the COVID-19 pandemic. Based on our findings, we highlight several issues and complications resulting from the pandemic concerning people with SUDs that should be tackled more efficiently during the future waves or similar pandemics. The issues and potential strategies comprise the following: (1) helping policymakers to generate business continuity plans, (2) maintaining the use of evidence-based interventions for people with SUDs, (3) being prepared for adequate medication supplies, (4) integrating harm reduction programs with other treatment modalities, and (5) having specific considerations for vulnerable groups such as immigrants and refugees. © Copyright © 2021 Radfar, De Jong, Farhoudian, Ebrahimi, Rafei, Vahidi, Yunesian, Kouimtsidis, Arunogiri, Massah, Deylamizadeh, Brady, Busse, ISAM-PPIG Global Survey Consortium, Potenza, Ekhtiari and Baldacchino. |
addiction services; COVID-19 pandemic; drug policy; harm reduction; opioid agonist treatment; public health; substance use disorder |
buprenorphine; methadone; adult; Article; commercial phenomena; controlled study; coronavirus disease 2019; drug dependence; drug dependence treatment; drug shortage; female; geographic distribution; harm reduction; health care access; health care management; health care personnel; health care policy; health care system; health program; high income country; human; immigrant; low income country; male; mental health care; mental health service; middle aged; middle income country; pandemic; questionnaire; refugee |
Frontiers Media S.A. |
16640640 |
|
|
Article |
Q1 |
1363 |
2668 |
|
|
|
456 |
Bahtiar A., Setyowati H., Mahanani R., Wati A., Arsianti A., Fadilah F. |
35365874400;57223255498;57223266884;57223271215;36124567000;56966708600; |
Rhaponticin contained Rheum officinale root extract improved Postmenopause symptom of Ovariectomized Rat |
2021 |
Journal of Advanced Pharmaceutical Technology and Research |
12 |
2 |
|
175 |
179 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105384592&doi=10.4103%2fjaptr.JAPTR_324_20&partnerID=40&md5=1f1fbda205bf337ab7c1628298d5d1ba |
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI, Depok, 16424, Indonesia; Department of Medicinal Chemistry, Faculty of Medicine, Universitas Indonesia, Kampus UI Jl, Salemba Raya, Jakarta, Indonesia |
Bahtiar, A., Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI, Depok, 16424, Indonesia; Setyowati, H., Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI, Depok, 16424, Indonesia; Mahanani, R., Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI, Depok, 16424, Indonesia; Wati, A., Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI, Depok, 16424, Indonesia; Arsianti, A., Department of Medicinal Chemistry, Faculty of Medicine, Universitas Indonesia, Kampus UI Jl, Salemba Raya, Jakarta, Indonesia; Fadilah, F., Department of Medicinal Chemistry, Faculty of Medicine, Universitas Indonesia, Kampus UI Jl, Salemba Raya, Jakarta, Indonesia |
Postmenopausal women have decreased levels of the hormone estrogen. Reduced estrogen levels will often involve many symptoms that reduced quality of life. This research aims to analyze the effects of Rheum officinale root extract on postmenopausal model rats. To this end, thirty rats underwent ovariectomy (OVX) surgery and six rats were operated without having their ovaries removed. The OVX was confirmed by body weight-uterus weight ratio and a vaginal swab. Six groups of the rats were performed: SHAM group and negative control groups are given vehicle; the positive control was assigned tamoxifen; and the extract has been given three doses 7, 35, and 175 mg/200 g BW, respectively, for 30 days. The calcium content of bone ash was measured using atomic absorption spectrophotometer. Blood pressure was evaluated using CODA®, and the metabolites in the blood were assessed using gas chromatography-mass spectrometry (MS) and high-performance liquid chromatography. As a result, using ultra-performance liquid chromatography (UPLC)-MS, we found that the extract's major component was rhaponticin and its metabolites. The bone calcium levels increased with increasing doses of the extract. In the OVX group, the bone calcium content was decreased significantly 51.56% ± 8.9% g compared with the SHAM group 62.97% ±5.6% g, and the administration of Rheum extract could restore the calcium content of the bone to become 69.27% ± 3.8% g. From the above data, we concluded that Rheum root extracts contain astrigin, rhaponticin, rhapontigenin, and desoxyrhaponticin. Rheum root extract could improve calcium content and lipid profiles of OVX rats by stimulation osteoblastogenesis. Rheum root extracts could control the blood pressure of OVX rats by reducing lipid profiles. © 2021 Wolters Kluwer Medknow Publications. All rights reserved. |
Calcium; hypertension; Kalembak; lipid profiles; osteoporosis; postmenopausal; rhaponticin; Rheum officinale |
antihypertensive agent; astringin; calcium; cholesterol; desoxyrhaponticin; high density lipoprotein; low density lipoprotein; rhapontigenin; rhapontin; Rheum officinale extract; tamoxifen; triacylglycerol; unclassified drug; analytical parameters; animal experiment; animal model; animal tissue; antihypertensive activity; Article; atomic absorption spectrometry; blood pressure measurement; body weight; body weight gain; body weight uterus weight ratio; bone density; calcium bone level; comparative study; controlled study; diastolic blood pressure; drug effect; female; high performance liquid chromatography; hypertension; Indonesia; lipid fingerprinting; mass fragmentography; nonhuman; ovariectomy; plant root; postmenopause; priority journal; protein analysis; rat; rat model; retention time |
Wolters Kluwer Medknow Publications |
01105558 |
|
|
Article |
Q3 |
325 |
14045 |
|
|
|
494 |
Turu' Allo I.J., Santoso A., Findyartini A. |
57222645159;36905206100;56543777300; |
Cardiology trainees' attitudes towards clinical supervision: a scale development study |
2021 |
International journal of medical education |
12 |
|
|
38 |
44 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103608400&doi=10.5116%2fijme.604a.4964&partnerID=40&md5=d05fe194366331389db166e4ab3e2b62 |
Medical Education Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom; Department of Cardiology-Vascular Medicine, Faculty of Medicine, Universitas Indonesia/National Cardiovascular Centre-Harapan Kita HospitalJakarta, Indonesia; Department of Medical Education, Faculty of Medicine, Universitas IndonesiaJakarta, Indonesia |
Turu' Allo, I.J., Medical Education Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom; Santoso, A., Department of Cardiology-Vascular Medicine, Faculty of Medicine, Universitas Indonesia/National Cardiovascular Centre-Harapan Kita HospitalJakarta, Indonesia; Findyartini, A., Department of Medical Education, Faculty of Medicine, Universitas IndonesiaJakarta, Indonesia |
Objectives: This study aims to explore the construct validity, dimensionality, and internal consistency of a new attitude scale for measuring cardiology trainees' attitudes towards clinical supervision. Methods: A multi-centred, cross-sectional study involving 388 Indonesian cardiology trainees from eight universities was conducted using convenience sampling. Twenty-nine items have been generated based on an extensive literature review and conceptual framework of effective clinical supervision. Ten clinical experts reviewed the items to ensure the Cardiology Clinical Supervision Scale (CCSS) adequately represents the construct under study. An exploratory factor analysis using principal axis factoring (PAF) with oblique rotation was run to identify the internal structure of the scale. Items with factor loading <0.50 were deleted. In addition, inter-item correlations and items' communalities were analysed. Each subscale's internal consistency was assessed using Cronbach's alpha score. Results: The content validity index provided evidence for CCSS' validity (G-coefficient=0.71). Scrutinising the experts' comments, we finalised the scale to include 27 items. Further, four items were deleted due to low inter-item correlation and communality. PAF analysis resulted in a two-factor model comprising the "Supervisory Interaction and Facilitation" factor (n=10 items) and the "Role Modelling" factor (n=9 items); four items were deleted due to low factor loading. The Cronbach's alpha score for SIF and RM factors were 0.93 and 0.89, respectively. Conclusions: The study's results support the validity, internal structure, and internal consistency of the new clinical supervision scale for cardiology training. Further studies are required to investigate other validity and reliability evidence for CCSS, including its cross-cultural validity. |
cardiology training; clinical supervision; scale development |
attitude; cardiology; cross-sectional study; human; psychometry; questionnaire; reproducibility; Attitude; Cardiology; Cross-Sectional Studies; Humans; Psychometrics; Reproducibility of Results; Surveys and Questionnaires |
NLM (Medline) |
20426372 |
|
33772563 |
Article |
Q2 |
592 |
8541 |
|
|
